The purpose of this study is to compare two different doses of epinephrine in treating cardiac arrest patients. The study will test whether a lower dose (0.5 mg) works better than the standard dose (1 mg) in helping patients survive with good brain function. The medication will be given as a solution for injection through a vein during emergency treatment by medical teams.

During the study, patients will be randomly assigned to receive either the lower or standard dose of epinephrine. Neither the patients nor the medical team will know which dose is being given. The treatment will be provided as part of the emergency care when medical teams arrive to help someone experiencing cardiac arrest. The study will monitor how well patients recover over 28 days after their cardiac arrest.

The treatment involves giving medications through an intravenous bolus (a quick injection into a vein). Some patients will receive both isoprenaline and epinephrine, while others will receive epinephrine and a placebo. The study aims to determine if the combination of these medications can improve the chances of restarting the heart and maintaining its rhythm.

During the study, medical professionals will administer these treatments as part of standard emergency care procedures when they attend to people experiencing cardiac arrest outside of the hospital. The maximum dose of isoprenaline that may be given is 1600 micrograms per day. This research focuses specifically on cases where the heart has stopped in a way that cannot be treated with a defibrillator (the device that delivers electric shocks to the heart).

Participants in the study will receive either Levosimendan or a placebo while undergoing CPR for an out-of-hospital cardiac arrest. The study will monitor various outcomes, such as whether the heart starts beating again on its own, if the patient can be transported to the hospital, and the patient’s condition upon arrival at the hospital. The study will also look at the patient’s recovery and health status over time, including any organ function issues and neurological outcomes, which refer to the brain’s ability to function properly after the event.

The trial will also measure the levels of Levosimendan in the blood of those who receive it, to better understand how the body processes the medication. The study is expected to continue until 2027, with the goal of providing valuable information on the potential benefits of Levosimendan in improving survival and recovery after a cardiac arrest.

The purpose of the study is to determine if using this combination of medications can improve the chances of survival for patients 30 days after experiencing a cardiac arrest, compared to using adrenaline alone. During the study, some patients will receive the combination of medications, while others will receive only adrenaline. The study will monitor the patients’ health and survival over a period of time to gather results.

Participants in the study will be those who have experienced a cardiac arrest in a hospital setting and meet certain criteria for receiving adrenaline. The study aims to provide valuable information on whether this combination of medications can offer better outcomes for cardiac arrest patients.

The study uses several anti-seizure medications administered through a vein, including diazepam, midazolam, lorazepam, propofol, esketamine, lacosamide, levetiracetam, and sodium valproate. These medications are given in a step-by-step approach to stop the seizure activity that is detected by brain wave monitoring.

The research will compare patients who receive seizure treatment with those who do not receive treatment. The main focus is on how well patients recover their ability to function in daily life six months after their cardiac arrest. The study will also look at the cost-effectiveness of the treatment approach.

The purpose is to find out if isoprenaline is more effective than epinephrine at achieving sustained heartbeat restoration in patients whose hearts have stopped beating outside of a hospital setting. Both medications are given as liquid solutions that are injected into the bloodstream during resuscitation efforts.

During the study, emergency medical service personnel will give either isoprenaline or epinephrine to patients experiencing cardiac arrest. The maximum daily dose of isoprenaline that may be given is 2.4 milligrams, while the maximum daily dose of epinephrine is 4 milligrams. The treatment period lasts for one day, during which medical professionals will monitor how the patient’s heart responds to the medication.

The trial will observe how quickly the VOW procedure can be performed and how effective it is compared to other methods. It will also look at how long it takes for the newborn’s heart rate to return to normal after the epinephrine injection. The study will monitor any difficulties or failures during the procedure, such as problems with the umbilical cord or equipment issues, and will record any side effects that occur within 72 hours after the injection.

By gathering this information, the study aims to improve the success rate of resuscitating newborns in the delivery room. The findings could help healthcare professionals better understand the effectiveness of the VOW procedure and potentially improve outcomes for newborns experiencing cardiorespiratory arrest at birth.

The purpose of the study is to find out if adding landiolol hydrochloride to the standard treatment for cardiac arrest can decrease the time it takes for the heart to achieve a sustained return of spontaneous circulation (sROSC), which means the heart starts beating effectively on its own. Participants in the study will receive either the landiolol hydrochloride or a placebo through an intravenous injection, which means the medication is given directly into a vein. The study will monitor how quickly the heart starts beating again and will also look at other outcomes, such as survival after 24 hours and the patient’s neurological condition.

In addition to landiolol hydrochloride, the study involves the use of sodium chloride solution, which is a common fluid used in medical settings to help deliver medications intravenously. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. The trial aims to provide valuable information on whether landiolol hydrochloride can be an effective addition to the treatment of cardiac arrest, potentially improving outcomes for patients experiencing this life-threatening condition.

The study will involve administering the treatment through an intravenous infusion, which means the solution is given directly into a vein. Another solution, Plasmalyte A Viaflo, which contains a mix of electrolytes like magnesium chloride hexahydrate, potassium chloride, sodium chloride, sodium acetate trihydrate, and sodium gluconate, may also be used. The purpose of the study is to see if these treatments can help improve outcomes for patients by decreasing the extent of brain injury after a cardiac arrest.

Participants in the study will receive the treatment for a short period, and their progress will be monitored over time. The study will look at various outcomes, such as the level of certain proteins in the blood that indicate brain injury, the patient’s recovery in terms of brain function, and their overall health status during their stay in the hospital. The goal is to gather information that could lead to better treatments for people who have suffered a cardiac arrest and are in a coma.

Participants in the study will receive either esketamine or propofol through an injection into a vein. This will happen after they have been resuscitated, which means their heart has been restarted, and they need to be sedated for a procedure called intubation. Intubation involves placing a tube into the windpipe to help with breathing. The study will monitor the effects of these medications on the brain and overall recovery.

The trial will measure specific markers in the blood, such as neuron-specific enolase, which can indicate brain injury, 48 hours after the cardiac arrest. Additionally, the study will track the survival of participants and their recovery over several months. This information will help determine which medication might offer better protection for the brain following a cardiac arrest outside of a hospital.

During the trial, patients who have been successfully resuscitated from a cardiac arrest will receive the argon and oxygen mixture through a ventilator. The study will monitor how well patients tolerate this treatment and whether it helps in their recovery. The trial will also look at how the treatment affects the heart and brain, as well as overall organ function and survival over a period of up to six months.

In addition to the argon and oxygen mixture, the study will also involve a comparison with another gas mixture containing nitrous oxide and oxygen. This will help researchers understand the differences in outcomes between the two treatments. The trial aims to gather important information that could lead to better treatment options for patients who have suffered a cardiac arrest.

The purpose of the study is to determine if using this combination of medications can improve the chances of survival 30 days after a cardiac arrest, compared to using adrenaline alone. Participants in the study will receive either the combination of medications or the standard treatment with adrenaline. The study will monitor the participants over a period to assess their survival and recovery.

Throughout the study, participants will be closely observed by medical professionals to ensure their safety and to gather data on the effectiveness of the treatment. The study aims to provide valuable insights into improving treatment outcomes for cardiac arrest patients.

The purpose of this study is to find out if there is a difference in the return of a normal heartbeat, known as return of spontaneous circulation (ROSC), depending on the type of access used to deliver the medication. The study will compare two methods of delivering the medication: through a vein (intravenous) or directly into the bone (intraosseous). Participants in the study will receive one of these treatments during a cardiac arrest situation outside of a hospital.

The study will monitor participants to see if their heart starts beating again and if they survive. It will also look at their brain function 30 days after the event, using a scale called the modified Rankin Scale (mRS), which measures how well a person can perform daily activities. The study aims to provide valuable information on the best way to treat cardiac arrest outside of a hospital setting.

Participants in the study will receive either sodium bicarbonate or a placebo during the event of a cardiac arrest while they are in the hospital. The treatment will be given through an intravenous injection, which means it will be administered directly into a vein. The main goal of the study is to see if sodium bicarbonate can increase the likelihood of the heart resuming its normal function, known as the return of spontaneous circulation.

The study will also look at other important outcomes, such as survival rates 30 days after the cardiac arrest and whether patients have a favorable neurological outcome, which refers to the brain’s ability to function well after the event. This will be assessed using a scale that measures the level of disability. The trial is designed to provide valuable information on whether sodium bicarbonate can be an effective treatment during in-hospital cardiac arrest.

Participants in the study will receive vitamin C through an intravenous (IV) injection, which means it is given directly into a vein. The study will compare the effects of vitamin C with standard treatments, which may include other medications like dobutamine, epinephrine (also known as adrenaline), noradrenaline (also known as norepinephrine), and thiamine hydrochloride (vitamin B1). Some participants may receive a placebo instead of vitamin C. The study will monitor how quickly patients can stop using vasopressors and will also look at other outcomes, such as survival rates and neurological health, over a period of up to 28 days.

The purpose of this study is to determine if early treatment with high-dose vitamin C can improve recovery in patients who have suffered a cardiac arrest and are experiencing shock. The trial will help researchers understand if vitamin C can be a beneficial addition to the current standard treatments for this condition.

Participants in the study will receive either amiodarone or a placebo through an intravenous injection, which means the medication is given directly into a vein. The study will monitor the patients for any severe heart rhythm issues, such as ventricular fibrillation or ventricular tachycardia, which are types of irregular heartbeats that can be life-threatening and may require medical intervention. The study aims to see if amiodarone can help prevent these problems from occurring again after the initial cardiac arrest.

The trial will last for a period of 30 days from the time a patient is included in the study. During this time, researchers will closely observe the health outcomes of the participants to gather information on the effectiveness of amiodarone in improving survival rates and reducing the recurrence of severe heart rhythm disturbances. This research could provide valuable insights into better treatment options for patients who have suffered a cardiac arrest outside of a hospital setting.

Participants in the study will receive either the active medication or a placebo, and their progress will be monitored over a period of time. The study will also look at the effects of different physical positions, such as an elevated backrest, and the timing of waking up and removing breathing support after admission to the hospital. The main goal is to see how these interventions impact the number of days patients are alive outside the hospital within 30 days and overall survival at 90 days.

This study is important for understanding how to best support patients who have suffered a cardiac arrest outside of a hospital setting. By comparing these different treatments and approaches, researchers hope to find ways to improve outcomes and quality of life for these patients. The results could lead to better treatment guidelines and care practices for individuals recovering from cardiac arrest.

The medications being studied include Bisoprolol Fumarate, Hydrochlorothiazide, Metoprolol, Atenolol, Chlortalidone, Nadolol, and Propranolol Hydrochloride. These medications are taken orally, meaning they are swallowed in pill form. The study will compare the effects of these medications to see which is most effective in preventing further heart issues in patients with IVF.

Participants in the study will receive one of these medications or a placebo for up to 36 months. Throughout the study, patients will have regular check-ups to monitor their heart health and any changes in their condition. The study will also assess the quality of life of participants after one year. The goal is to determine which treatment is most beneficial for patients who have survived an unexplained cardiac arrest.

The research aims to determine if using these medications together leads to better outcomes for patients who have survived cardiac arrest but are experiencing circulatory problems. The medications are given through intravenous methods – either as an injection or continuous infusion. Hydrocortisone is administered at doses up to 200 mg per day, while argipressin is given through continuous infusion for up to three days.

During the study, patients receive either the combination of both active medications or their matching placebos. The treatment continues for up to seven days for hydrocortisone and three days for argipressin. Patients’ recovery is monitored for 30 days after treatment, with special attention to their brain function and overall survival. The medications are administered along with standard medical care that all patients receive in the intensive care unit.